Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety and tolerability of a range of
BIIB037 doses administered as single intravenous (IV) infusions in participants with mild to
moderate Alzheimer's Disease (AD). Secondary objectives of this study in this study
population are to assess the pharmacokinetics(PK) and to evaluate the immunogenicity of
BIIB037 after single-dose administration.